Psilocybin for Treatment of OCD-2

Randomised, triple-masked Phase I/II parallel-group trial of 20 symptomatic, medication-free OCD patients assigned to low (10 mg) or high (30 mg) psilocybin across four supervised oral dosing sessions separated by three weeks.

Outcomes include Y-BOCS severity, functioning and quality of life, safety and tolerability measures, subjective experience, and mechanistic measures including fMRI and EEG; follow-up to 12 weeks will assess durability and adverse events.